지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.1
- 수록면
- 45 - 52 (8page)
이용수
초록· 키워드
오류제보하기
Teriparatide (TPTD) is a bone-forming agent used to treat postmenopausal osteoporosis. Since hip fractures are related to higher morbidity and mortality rates than other fractures, efficacious osteoporosis drugs for the hip are critical. We reviewed research articles reporting the efficacy of TPTD in terms of bone mineral density (BMD), fractures prevention, changes in the outer diameter, cortical thickness and porosity, post-operative periprosthetic BMD loss, and healing of typical and atypical fractures of the hip. Data meta-analyses indicated that TPTD not only increased the BMD of the proximal femur but also decreased the risk of hip fractures. Even though TPTD increases the cortical bone porosity of the proximal femur, the bone strength does not decrease as the majority of the porosity is located at the endocortex; further, it increases the outer diameter and thickens the cortical bone. TPTD stimulates bone remodeling and facilitates callus maturity and fracture healing. There have been many reports on improving the effect of TPTD on the healing of atypical fractures; therefore it is advisable to use TPTD considering the increase benefit compared to the risk.
목차
등록된 정보가 없습니다.
참고문헌 (61)
참고문헌 신청
Shoback D / 2020 / Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update / J Clin Endocrinol Metab 105:dgaa048
Lloyd R / 2019 / Co-morbidities in patients with a hip fracture / Ulster Med J 88:162~166
Langdahl BL / 2009 / Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide : 18-month data from the European Forsteo Observational Study(EFOS) / Calcif Tissue Int 85:484~493
Graeff C / 2007 / Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo : results from the EUROFORS study / J Bone Miner Res 22:1426~1433
Schnell R / 2010 / Changes in cross-sectional area of spinal canal and vertebral body under 2 years of teriparatide treatment : results from the EUROFORS study / Calcif Tissue Int 87:130~136
Lloyd R / 2019 / Co-morbidities in patients with a hip fracture / Ulster Med J 88:162~166
Langdahl BL / 2009 / Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide : 18-month data from the European Forsteo Observational Study(EFOS) / Calcif Tissue Int 85:484~493
Graeff C / 2007 / Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo : results from the EUROFORS study / J Bone Miner Res 22:1426~1433
Schnell R / 2010 / Changes in cross-sectional area of spinal canal and vertebral body under 2 years of teriparatide treatment : results from the EUROFORS study / Calcif Tissue Int 87:130~136
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Two-Year Outcomes of Daily and Twice-Weekly Teriparatide Treatment in Postmenopausal Women with Severe Osteoporosis: A Randomized Non-Blinded Prospective Study
대한골대사학회지
2024 .05
-
Does Teriparatide Improve Fracture Union?: A Systematic Review
대한골대사학회지
2020 .01
-
Effect of Teriparatide on Healing of Atypical Femoral Fractures: A Systemic Review
대한골대사학회지
2015 .01
-
Effects of treatment interruption due to patient convenience on treatment of once a week teriparatide
Osteoporosis and Sarcopenia
2020 .01
-
Effect of Osteoporosis Medication on Fracture Healing: An Evidence Based Review
대한골대사학회지
2020 .01
-
Comparative effect of alendronate and teriparatide on bone mineral density and bone turnover among Japanese postmenopausal women with history of fragility fractures: A clinical practice-based observational study
Osteoporosis and Sarcopenia
2015 .01
-
Efficacy of once-weekly and twice-weekly injections of teriparatide by patient characteristics: A post hoc analysis of the TWICE study
Osteoporosis and Sarcopenia
2021 .01
-
Adjuvant Teriparatide Therapy for Surgical Treatment of Femoral Fractures; Does It Work?
Hip and Pelvis
2016 .01
-
Bone Health Evaluations and Secondary Fragility Fractures in Hip Fracture Patients
Hip and Pelvis
2024 .03
-
Effects of Teriparatide on Treatment Outcomes in Osteoporotic Hip and Pelvic Bone Fractures: Meta-analysis and Systematic Review of Randomized Controlled Trials
Hip and Pelvis
2020 .01
-
The incidence of hip fracture and mortality rate after hip fracture in Korea: A nationwide population-based cohort study
Osteoporosis and Sarcopenia
2019 .01
-
Recent Epidemiology of Hip Fractures in South Korea
Hip and Pelvis
2020 .01
-
An updated hip fracture projection in Asia: The Asian Federation of Osteoporosis Societies study
Osteoporosis and Sarcopenia
2018 .01
-
Effects of Weekly Teriparatide Administration for Vertebral Stability and Bony Union in Patients with Acute Osteoporotic Vertebral Fractures
Asian Spine Journal
2019 .01
-
Effects of teriparatide on bone in autochthonous transgenic model mice for diabetes mellitus (Akita mice)
Osteoporosis and Sarcopenia
2019 .01
-
Osteoporosis treatment rates after hip fracture 2011?2019 in Hawaii: Undertreatment of men after hip fractures
Osteoporosis and Sarcopenia
2021 .09
-
The importance of updating osteoporotic femur fracture data: Asian Federation of Osteoporosis Societies study
Osteoporosis and Sarcopenia
2018 .01
-
Second hip fracture in Hong Kong – Incidence, demographics, and mortality
Osteoporosis and Sarcopenia
2020 .01
-
Hip fracture is associated with a reduced risk of type 2 diabetes: A retrospective cohort study
Osteoporosis and Sarcopenia
2024 .06
-
Comparison of morbidity and mortality of hip and vertebral fragility fractures: Which one has the highest burden?
Osteoporosis and Sarcopenia
2020 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0